RBC Capital Lowers Illumina's Price Target to $128, Maintains Outperform Rating
Mar 13, 2025 15:59
CST Updated
15:59
Illumina
Diagnostic Product Developer
Gelonghui March 13 | RBC Capital: Downgraded Illumina's target price from $247 to $128, maintaining an "Outperform" rating. (Gelonghui)